Income statement
USD
Annual
| Metric | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|
| Revenue | 571K | 0 | 0 | 264K | 0 |
| Gross Profit | 571K | 0 | 0 | 264K | 0 |
| Operating Income | -997K | -880K | -853K | -2M | -4M |
| EBITDA | -969K | -824K | -790K | -838K | -4M |
| Net Income | -1M | -1M | -2M | -3M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.00002
+0.00% today
1Y Change
-80.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Viropro Inc. (VPRO) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 80.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow +6.9% with operating margin -174.5% and ROIC 0.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Stock Foundry combines VPRO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VPRO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VPRO Max Drawdown
-99.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VPRO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$4.4M
-67.1% YoY
Free Cash Flow
-$1.4M
-87.9% YoY
Revenue Growth
+0.0%
EPS Growth
+0.0%
Gross Margin
100.0%
Net Margin
-176.9%
Income statement
USD
| Metric | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|
| Revenue | 571K | 0 | 0 | 264K | 0 |
| Gross Profit | 571K | 0 | 0 | 264K | 0 |
| Operating Income | -997K | -880K | -853K | -2M | -4M |
| EBITDA | -969K | -824K | -790K | -838K | -4M |
| Net Income | -1M | -1M | -2M | -3M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|
| Cash & Equivalents | 59K | 55K | 3K | 40K | 97K |
| Total Assets | 2M | 62K | 130K | 1M | 2M |
| Total Liabilities | 657K | 430K | 2M | 1M | 1M |
| Shareholder Equity | 1M | -369K | -1M | -271K | 504K |
| Total Debt | 176K | 100K | 1M | 648K | 547K |
| Net Debt | 117K | 45K | 1M | 608K | 450K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
-86.7% YoY
Capital Expenditures
9K
Free Cash Flow
1M
-87.9% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
-174.5%
Net Margin
-176.9%
ROE
-185.7%
Debt / Equity
0.12x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.